Health Tech Investment Act

Legislative bill overview

HR 6197, the Health Tech Investment Act, is a bipartisan bill introduced in November 2025 that aims to incentivize and facilitate investment in health technology innovation. The bill has been referred to both the Energy and Commerce Committee and the Ways and Means Committee, suggesting it likely contains provisions affecting healthcare regulation, tax incentives, or both.

Why is this important

Health technology innovation can significantly improve patient outcomes, reduce healthcare costs, and enhance system efficiency—but requires substantial capital investment that may be deterred by regulatory or financial barriers. This bill appears designed to address those barriers through legislative mechanisms, potentially affecting billions in healthcare sector investment decisions and ultimately patient access to new medical technologies and solutions.

Potential points of contention

• Tax incentive scope and cost: The bill likely includes tax breaks or credits for health tech investments, which critics may argue reduces federal revenue while primarily benefiting well-capitalized investors rather than patients directly
• Regulatory tradeoffs: Incentive provisions could clash with concerns that expedited approval pathways or reduced regulatory requirements might compromise safety standards or patient protections
• Definitional boundaries: Disagreement may arise over what qualifies as "health technology" for incentive purposes—whether it includes pharmaceuticals, medical devices, digital health platforms, or other categories with different stakeholder interests